Tandem Diabetes Care, Inc. $TNDM Stock Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. trimmed its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 66.7% in the third quarter, HoldingsChannel.com reports. The firm owned 422,252 shares of the medical device company’s stock after selling 844,237 shares during the period. Jefferies Financial Group Inc.’s holdings in Tandem Diabetes Care were worth $6,887,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fulcrum Asset Management LLP raised its position in shares of Tandem Diabetes Care by 1,463.6% during the third quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock worth $73,000 after acquiring an additional 4,098 shares during the last quarter. Provenance Wealth Advisors LLC bought a new position in Tandem Diabetes Care during the 3rd quarter worth approximately $158,000. Summit Global Investments raised its holdings in Tandem Diabetes Care by 13.9% during the 3rd quarter. Summit Global Investments now owns 24,753 shares of the medical device company’s stock worth $404,000 after purchasing an additional 3,017 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in Tandem Diabetes Care by 31.3% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 34,400 shares of the medical device company’s stock worth $561,000 after purchasing an additional 8,200 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its position in shares of Tandem Diabetes Care by 849.0% in the 3rd quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock worth $38,000 after purchasing an additional 2,080 shares during the period.

Tandem Diabetes Care Stock Performance

Shares of Tandem Diabetes Care stock opened at $17.51 on Friday. The stock has a fifty day simple moving average of $17.41 and a 200 day simple moving average of $18.84. Tandem Diabetes Care, Inc. has a 12-month low of $12.26 and a 12-month high of $29.65. The company has a current ratio of 3.20, a quick ratio of 2.65 and a debt-to-equity ratio of 4.47.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.15. The business had revenue of $283.69 million for the quarter, compared to analysts’ expectations of $265.85 million. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The business’s revenue was up 13.8% on a year-over-year basis. During the same period last year, the business earned ($0.31) EPS. Sell-side analysts expect that Tandem Diabetes Care, Inc. will post -0.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the transaction, the director owned 24,434 shares in the company, valued at $467,911.10. This represents a 6.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on TNDM shares. Truist Financial lowered their target price on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, September 24th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $26.00 target price (down from $30.00) on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Barclays lifted their target price on Tandem Diabetes Care from $18.00 to $20.00 and gave the stock an “equal weight” rating in a report on Friday, November 6th. Wells Fargo & Company cut their price target on Tandem Diabetes Care from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, November 6th. Finally, Mizuho set a $20.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tandem Diabetes Care has an average rating of “Hold” and an average target price of $27.18.

View Our Latest Stock Report on Tandem Diabetes Care

Tandem Diabetes Care Profile

(Free Report)

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

Recommended Stories

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.